Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equecabtagene Autoleucel in Lenalidomide-Refractory RRMM
NCT06464991Phase 3Recruiting
- Sponsor
- Reindeer Biotech
- Start
- Mar 2024
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of equecabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Reindeer Biotech. Primary endpoint: Progression-Free Survival up to 5 years. Started Mar 2024; status: recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06464991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464991.